Skip to main content

Table 2 Baseline patient, tumor, and treatment characteristics for all patients (n = 115) and broken down by patients did or did not experience SL

From: Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC

Characteristic Total (N = 115) SL (N = 63) No SL (N = 52) P value
Age at diagnosis, years, Median (IQR) 63.00 (59.00–67.00) 63.00 (60.00–67.00) 62.50 (55.50–67.00) 0.362
Sex
 Male 107 (92.2%) 59 (51.3%) 48 (41.7%)  
 Female 8 (7.0%) 4 (3.5%) 4 (3.5%) 0.778
ECOG performance status
 0–1 84 (73.0%) 44 (38.3%) 40 (34.8%)  
 2 31 (27.0%) 19 (16.5%) 12 (10.4%) 0.394
Smoking pack-years  
 ≥ 10 80 45 35  
 0–10 4 3 1  
 0 24 12 12  
 Unkown 7 3 4 0.717
Histology
 Squamous carcinoma 78 (67.8%) 49 (42.2%) 35 (30.4%)  
 Adenocarcinoma 34 (29.6%) 19 (16.5%) 15 (13.0%)  
 Others 3 (2.6%) 1 (0.9%) 2 (1.7%) 0.683
cT stage (AJCC 8th ed)
 T1 14 (12.2%) 8 (7.0%) 6 (5.2%)  
 T2 31 (26.7%) 20 (17.2%) 11 (9.57%)  
 T3 27 (23.5%) 12 (10.4%) 15 (13.0%)  
 T4 43 (37.4%) 23 (20.0%) 20 (17.4%) 0.492
cN stage
 N1 6 (5.2%) 2 (1.7%) 4 (3.5%)  
 N2 73 (63.5%) 39 (33.9%) 34 (29.6%)  
 N3 36 (31.3%) 22 (19.1%) 14 (12.2%) 0.417
Stage
 IIIA 33 (28.7%) 18 (15.7%) 15 (13.0%)  
 IIIB 61 (53.0%) 33 (28.7%) 28 (24.3%)  
 IIIC 21 (18.3%) 12 (10.4%) 9 (7.8%) 0.971
TLCs, cells/μL (median, IQR)
 Baseline 1600 (1400–2000) 1600 (1300–1900) 1800 (1400–2200) 0.037
 Pre-RT 1800 (1400–2100) 1600 (1280–1900) 1965 (1700–2252) <  0.001
 TLC nadir during the course of RT 500 (380–700) 390 (300–470) 700 (600–830) <  0.001
 1 month after RT 915 (700–1100) 800 (598–1100) 995 (882–1232) 0.004
 2 month after RT 900 (700–1100) 740 (600–982) 1000 (810–1195) <  0.001
Tumor volume, cm3 (median, IQR)  
 GTV 56.85 (32.47–129.35) 87.69 (45.58–144.92) 43.40 (21.84–95.52) 0.006
 PTV 146.03 (74.20–247.39) 160.95 (80.69–258.92) 124.82 (71.13–224.05) 0.192
EQD2 (Gy or Gy[RBE]) (median, IQR) 64.00 (60.00–65.00) 62.87 (60.00–65.10) 65.00 (60.00–65.00) 0.755
BED (Gy) 76.80 (72.00–78.00) 75.44 (72.00–78.13) 78 (72–78) 0.768
Fractions, number (median, IQR) 25 (20–30) 25 (25–30) 25 (20–30) 0.141
OTT, days (median, IQR) 39 (31–43) 39 (33–43) 35 (29–43) 0.281
Key mean normal tissue doses, cGy (median, IQR)
 Mean lung dose 1275 (1078–1454) 1354.90 (1146.00–1480.00) 1165 (990–1386) 0.007
 Mean heart dose 601 (420–1261.50) 886 (439.00–1502.25) 518 (384–936.90) 0.041
Radiation technique
 3D conformal 28 (24.3%) 16 (13.9%) 12 (10.4%)  
 Intensity modulated 37 (32.2%) 19 (16.5%) 18 (15.7%)  
 Helical Tomotherapy 50 (43.5%) 28 (24.3%) 22 (19.1%) 0.874
Concurrent chemoradiation (sequential)
 Yes 31 (27.0%) 15 (12.9%) 16 (13.9%)  
 No 84 (73.0%) 48 (41.7%) 36 (31.3%) 0.403
Induction chemotherapy
 Yes 91 (79.1%) 54 (47.0%) 37 (32.2%)  
 No 24 (20.9%) 9 (7.8%) 15 (13.0%) 0.056
Adjuvant chemotherapy
 Yes 61 (53.0%) 31 (27.0%) 30 (26.1%)  
 No 54 (47.0%) 32 (27.8%) 22 (19.1%) 0.364
  1. Abbreviations: SL severe lymphopenia, IQR interquartile range, ECOG Eastern Cooperative Oncology Group, AJCC American Joint Committee on Cancer, TLCs total peripheral lymphocyte counts, GTV gross tumor volume, PTV planning target volume, EQD2 equivalents (relative biological equivalents), BED biological effective dose, OTT overall treatment time